Biologic drugs rack up billions in annual U.S. sales. Here’s a solution to lower the costs.
By Peter B. Bach and Mark R. Trusheim
Dr. Bach is the director of the Drug Pricing Lab and Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. Mr. Trusheim is a visiting scientist at the M.I.T. Sloan School of Management.
March 15, 2021
Credit.Illustration by Mark Harris; Photographs by Wavebreakmedia and Nerthuz, via Getty Images
For around two decades, Roche’s breast cancer drug Herceptin has prolonged the lives of people with breast cancer, and AbbVie’s immunosuppressive drug Humira has eased the symptoms of rheumatoid arthritis patients.